Methylprednisolone hemisuccinate

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Summary

Methylprednisolone hemisuccinate is a water soluble corticosteroid used to treat severe allergic reactions, dermatologic diseases, endocrine disorders, gastrointestinal diseases, hematological disorders, neoplastic diseases, nervous system conditions, ophthalmic diseases, renal diseases, respiratory diseases, and rheumatic disorders.

Brand Names
Solu-medrol
Generic Name
Methylprednisolone hemisuccinate
DrugBank Accession Number
DB14644
Background

A water-soluble ester of methylprednisolone used for cardiac, allergic, and hypoxic emergencies.

Type
Small Molecule
Groups
Approved
Structure
Thumb
Weight
Average: 474.55
Monoisotopic: 474.225368055
Chemical Formula
C26H34O8
Synonyms
  • Methylprednisolone hemisuccinate
  • Methylprednisolone hydrogen succinate
  • Methylprednisolone succinate

Pharmacology

Indication

Not Available

Pharmacology
Accelerate your drug discovery research with the industry’s only fully connected ADMET dataset, ideal for:
Machine Learning
Data Science
Drug Discovery
Accelerate your drug discovery research with our fully connected ADMET dataset
Learn more
Associated Conditions
Associated Therapies
Contraindications & Blackbox Warnings
Contraindications
Contraindications & Blackbox Warnings
With our commercial data, access important information on dangerous risks, contraindications, and adverse effects.
Learn more
Our Blackbox Warnings cover Risks, Contraindications, and Adverse Effects
Learn more
Pharmacodynamics

Methylprednisolone sodium succinate (the sodium salt of methylprednisolone hemisuccinate) has the same metabolic and anti-inflammatory actions as methylprednisolone. When given parenterally and in equimolar quantities, the two compounds are equivalent in biologic activity.

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Medicalerrors
Reduce medical errors
and improve treatment outcomes with our comprehensive & structured data on drug adverse effects.
Learn more
Reduce medical errors & improve treatment outcomes with our adverse effects data
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AcarboseThe risk or severity of hyperglycemia can be increased when Methylprednisolone hemisuccinate is combined with Acarbose.
AceclofenacThe risk or severity of gastrointestinal irritation can be increased when Methylprednisolone hemisuccinate is combined with Aceclofenac.
AcemetacinThe risk or severity of gastrointestinal irritation can be increased when Methylprednisolone hemisuccinate is combined with Acemetacin.
AcenocoumarolMethylprednisolone hemisuccinate may increase the anticoagulant activities of Acenocoumarol.
AcetohexamideThe risk or severity of hyperglycemia can be increased when Methylprednisolone hemisuccinate is combined with Acetohexamide.
AcetyldigitoxinThe risk or severity of adverse effects can be increased when Methylprednisolone hemisuccinate is combined with Acetyldigitoxin.
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Methylprednisolone hemisuccinate is combined with Acetylsalicylic acid.
AlbiglutideThe risk or severity of hyperglycemia can be increased when Methylprednisolone hemisuccinate is combined with Albiglutide.
AlclofenacThe risk or severity of gastrointestinal irritation can be increased when Methylprednisolone hemisuccinate is combined with Alclofenac.
AldesleukinThe therapeutic efficacy of Aldesleukin can be decreased when used in combination with Methylprednisolone hemisuccinate.
Interactions
Improve patient outcomes
Build effective decision support tools with the industry’s most comprehensive drug-drug interaction checker.
Learn more
Food Interactions
No interactions found.

Products

Products
Comprehensive & structured drug product info
From application numbers to product codes, connect different identifiers through our commercial datasets.
Learn more
Easily connect various identifiers back to our datasets
Learn more
Product Ingredients
IngredientUNIICASInChI Key
Methylprednisolone sodium succinateLEC9GKY20K2375-03-3FQISKWAFAHGMGT-SGJOWKDISA-M
Brand Name Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
Solu-MedrolInjection, powder, for solution500 mg/1mLIntramuscular; IntravenousUNSPECIFIED2006-06-082006-06-08US flag
Solu-MedrolInjection, powder, for solution40 mg/1mLIntramuscular; IntravenousCardinal Health1959-04-02Not applicableUS flag
Solu-MedrolInjection, powder, for solution125 mg/2mLIntramuscular; IntravenousCardinal Health1959-04-02Not applicableUS flag
Solu-MedrolInjection, powder, lyophilized, for solution125 mg/1mLIntramuscular; IntravenousGeneral Injectables & Vaccines2010-09-012017-01-16US flag
Solu-medrolInjection, powder, for solution40 mg/1mLIntramuscular; IntravenousPhysicians Total Care, Inc.1959-04-022012-06-30US flag
Solu-medrolInjection, powder, for solution2 g/30.6mLIntramuscular; IntravenousPharmacia and Upjohn Company LLC1959-04-02Not applicableUS flag
Solu-MedrolInjection2 g/30.6mLIntramuscular; IntravenousPharmacia and Upjohn Company LLC1959-04-022021-01-31US flag
Solu-medrolInjection, powder, for solution40 mg/1mLIntramuscular; IntravenousPhysicians Total Care, Inc.1959-04-022012-06-30US flag
Solu-MedrolInjection, powder, for solution40 mg/1mLIntramuscular; IntravenousGeneral Injectables & Vaccines, Inc2010-04-01Not applicableUS flag
Solu-medrolInjection, powder, for solution125 mg/2mLIntramuscular; IntravenousMedical Purchasing Solutions, Llc1959-04-02Not applicableUS flag
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
A-methapredInjection, powder, lyophilized, for solution125 mg/2mLIntramuscular; IntravenousHospira, Inc.2006-10-062010-07-01US flag
A-methapredInjection, powder, for solution40 mg/1mLIntramuscular; IntravenousHospira, Inc.2009-07-142013-05-01US flag
A-methapredInjection, powder, lyophilized, for solution40 mg/1mLIntramuscular; IntravenousHospira, Inc.2006-10-062010-07-01US flag
A-methapredInjection, powder, for solution125 mg/2mLIntramuscular; IntravenousHospira, Inc.2009-06-222013-05-01US flag
Methylprednisolone Sodium SuccinateInjection, powder, lyophilized, for solution40 mg/1mLIntramuscular; IntravenousFresenius Kabi USA, LLC2004-11-30Not applicableUS flag
Methylprednisolone Sodium SuccinateInjection, powder, lyophilized, for solution500 mg/1Intramuscular; IntravenousAuroMedics Pharma LLC2015-12-15Not applicableUS flag
Methylprednisolone Sodium SuccinateInjection, powder, lyophilized, for solution500 mg/4mLIntramuscular; IntravenousBedford Pharmaceuticals2007-03-012009-06-30US flag
Methylprednisolone Sodium SuccinateInjection, powder, lyophilized, for solution500 mg/8mLIntramuscular; IntravenousGeneYork Pharmaceuticals Group LLC2021-04-20Not applicableUS flag
Methylprednisolone Sodium SuccinateInjection, powder, lyophilized, for solution125 mg/2mLIntramuscular; IntravenousREMEDYREPACK INC.2020-11-15Not applicableUS flag
Methylprednisolone Sodium SuccinateInjection, powder, lyophilized, for solution1 g/16mLIntramuscular; IntravenousBedford Pharmaceuticals2008-01-222009-11-30US flag

Categories

Drug Categories
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
5GMR90S4KN
CAS number
2921-57-5
InChI Key
IMBXEJJVJRTNOW-XYMSELFBSA-N
InChI
InChI=1S/C26H34O8/c1-14-10-16-17-7-9-26(33,20(29)13-34-22(32)5-4-21(30)31)25(17,3)12-19(28)23(16)24(2)8-6-15(27)11-18(14)24/h6,8,11,14,16-17,19,23,28,33H,4-5,7,9-10,12-13H2,1-3H3,(H,30,31)/t14-,16-,17-,19-,23+,24-,25-,26-/m0/s1
IUPAC Name
4-{2-[(1R,3aS,3bS,5S,9aR,9bS,10S,11aS)-1,10-dihydroxy-5,9a,11a-trimethyl-7-oxo-1H,2H,3H,3aH,3bH,4H,5H,7H,9aH,9bH,10H,11H,11aH-cyclopenta[a]phenanthren-1-yl]-2-oxoethoxy}-4-oxobutanoic acid
SMILES
[H][C@@]12CC[C@](O)(C(=O)COC(=O)CCC(O)=O)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])C[C@H](C)C2=CC(=O)C=C[C@]12C

References

General References
  1. FDA Approved Drug Products: Solu-Medrol (methylprednisolone sodium succinate) for injection [Link]
ChemSpider
16034
ChEBI
135765
ChEMBL
CHEMBL1201265
ZINC
ZINC000003977781
Wikipedia
Methylprednisolone

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4CompletedTreatmentAlopecia Totalis (AT) / Alopecia Universalis (AU) / Ophiasic Alopecia1
4CompletedTreatmentAsthma1
4CompletedTreatmentSepsis1
4CompletedTreatmentViral Bronchiolitis1
4Enrolling by InvitationTreatmentOrthopedic Surgeries1
4Not Yet RecruitingTreatmentGlomerulonephritis / Immunoglobulin A Nephropathy1
3CompletedTreatmentSudden Deafness1
3Not Yet RecruitingTreatmentCommunity Acquired Pneumonia (CAP)1
3RecruitingTreatmentCoronavirus Disease 2019 (COVID‑19) / Paediatric Inflammatory Multisystem Syndrome-Temporally Associated With SARS-CoV-2 (PIMS-TS)1
2CompletedTreatmentAccelerated Phase Chronic Myelogenous Leukemia / Adult Acute Lymphoblastic Leukemia in Remission / Adult Acute Megakaryoblastic Leukemia (M7) / Adult Acute Monoblastic Leukemia (M5a) / Adult Acute Monocytic Leukemia (M5b) / Adult Acute Myeloblastic Leukemia With Maturation (M2) / Adult Acute Myeloblastic Leukemia Without Maturation (M1) / Adult Acute Myeloid Leukemia in Remission / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(15;17)(q22;q12) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Adult Acute Myelomonocytic Leukemia (M4) / Adult Acute Promyelocytic Leukemia (M3) / Adult Erythroleukemia (M6a) / Adult Nasal Type Extranodal NK/T-Cell Lymphoma / Adult Pure Erythroid Leukemia (M6b) / Anaplastic Large Cell Lymphoma / Anaplastic Large-Cell Lymphoma / Angioimmunoblastic T-Cell Lymphoma / Burkitt's Lymphoma / Childhood Acute Erythroleukemia (M6) / Childhood Acute Lymphoblastic Leukemia in Remission / Childhood Acute Megakaryocytic Leukemia (M7) / Childhood Acute Monoblastic Leukemia (M5a) / Childhood Acute Monocytic Leukemia (M5b) / Childhood Acute Myeloblastic Leukemia With Maturation (M2) / Childhood Acute Myeloblastic Leukemia Without Maturation (M1) / Childhood Acute Myeloid Leukemia in Remission / Childhood Acute Myelomonocytic Leukemia (M4) / Childhood Acute Promyelocytic Leukemia (M3) / Childhood Chronic Myelogenous Leukemia / Childhood Myelodysplastic Syndromes / Chronic Phase Chronic Myelogenous Leukemia / Cutaneous B-Cell Non-Hodgkin Lymphoma / De Novo Myelodysplastic Syndromes / Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue / Hepatosplenic T-Cell Lymphoma / Intraocular Lymphoma / Nodal marginal zone B-cell lymphomas / Peripheral T-Cell Lymphoma (PTCL) / Post Transplant Lymphoproliferative Disorder / Previously Treated Myelodysplastic Syndromes / Recurrent Adult Acute Lymphoblastic Leukemia / Recurrent Adult Acute Myeloid Leukemia / Recurrent Adult Burkitt Lymphoma / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Adult Diffuse Mixed Cell Lymphoma / Recurrent Adult Diffuse Small Cleaved Cell Lymphoma / Recurrent Adult Grade III Lymphomatoid Granulomatosis / Recurrent Adult Hodgkin's Lymphoma / Recurrent Adult Immunoblastic Large Cell Lymphoma / Recurrent Adult Lymphoblastic Lymphoma / Recurrent Adult Non-Hodgkin Lymphoma / Recurrent Adult T-Cell Leukemia/Lymphoma / Recurrent Childhood Acute Lymphoblastic Leukemia / Recurrent Childhood Acute Myeloid Leukemia / Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Mycosis Fungoides/Sezary Syndrome / Recurrent Small Lymphocytic Lymphoma / Refractory Multiple Myeloma / Relapsing Chronic Myelogenous Leukemia / Secondary Myelodysplastic Syndromes / Small Intestine Lymphoma / Splenic Marginal Zone Lymphoma / Testicular Lymphoma / Waldenström's Macroglobulinemia (WM)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
Injection, powder, for solutionIntramuscular; Intravenous125 mg/2mL
Injection, powder, lyophilized, for solutionIntravenous
Injection, solutionIntramuscular; Intravenous
Injection, powder, for solutionParenteral
Injection, powder, for solutionIntramuscular; Intravenous
Injection, powder, for solutionIntramuscular; Intravenous1 g/1
Injection, powder, for solutionIntramuscular; Intravenous125 MG
Injection, powder, for solutionIntramuscular; Intravenous500 mg/1
Injection, powder, for solutionIntramuscular; Intravenous500 MG
Injection, powder, lyophilized, for solution
Injection, powder, lyophilized, for solutionIntramuscular; Intravenous1 g/16mL
Injection, powder, lyophilized, for solutionIntramuscular; Intravenous1 g/8mL
Injection, powder, lyophilized, for solutionIntramuscular; Intravenous125 mg/1
Injection, powder, lyophilized, for solutionIntramuscular; Intravenous125 mg/2mL
Injection, powder, lyophilized, for solutionIntramuscular; Intravenous2 g/30.6mL
Injection, powder, lyophilized, for solutionIntramuscular; Intravenous2 g/1
Injection, powder, lyophilized, for solutionIntramuscular; Intravenous40 mg/1
Injection, powder, lyophilized, for solutionIntramuscular; Intravenous40 mg/1mL
Injection, powder, lyophilized, for solutionIntramuscular; Intravenous500 mg/1
Injection, powder, lyophilized, for solutionIntramuscular; Intravenous500 mg/8mL
Injection, powder, lyophilized, for solutionIntramuscular; Intravenous500 mg/4mL
Injection, powder, for solution
Tablet
PowderIntramuscular; Intravenous1000 mg/1vial
InjectionIntramuscular; Intravenous2 g/30.6mL
Injection, powder, for solutionIntracavernous; Intramuscular40 mg/1
Injection, powder, for solutionIntramuscular; Intravenous1 g/1mL
Injection, powder, for solutionIntramuscular; Intravenous1 g/8mL
Injection, powder, for solutionIntramuscular; Intravenous125 mg/1mL
Injection, powder, for solutionIntramuscular; Intravenous2 g/30.6mL
Injection, powder, for solutionIntramuscular; Intravenous40 mg/1mL
Injection, powder, for solutionIntramuscular; Intravenous500 mg/1mL
Injection, powder, for solutionIntramuscular; Intravenous500 mg/4mL
Injection, powder, for solutionIntravenous1 g/1
Injection, powder, lyophilized, for solutionIntramuscular; Intravenous125 mg/1mL
Powder, for solutionIntravenous125 mg/1mL
PowderIntramuscular; Intravenous125 mg/1vial
PowderIntramuscular; Intravenous40 mg/1vial
PowderIntramuscular; Intravenous500 mg/1vial
Injection, powder, lyophilized, for solutionIntramuscular; Intravenous
PowderIntramuscular; Intravenous
InjectionIntramuscular; Intravenous
Powder, for solutionIntramuscular; Intravenous; Rectal125 mg / vial
Powder, for solutionIntramuscular; Intravenous; Rectal40 mg / vial
InjectionParenteral
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0264 mg/mLALOGPS
logP2.43ALOGPS
logP1.83ChemAxon
logS-4.2ALOGPS
pKa (Strongest Acidic)3.66ChemAxon
pKa (Strongest Basic)-2.9ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count7ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area138.2 Å2ChemAxon
Rotatable Bond Count7ChemAxon
Refractivity123.09 m3·mol-1ChemAxon
Polarizability49.87 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Enzymes

Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Inducer
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Dvorak Z, Pavek P: Regulation of drug-metabolizing cytochrome P450 enzymes by glucocorticoids. Drug Metab Rev. 2010 Nov;42(4):621-35. doi: 10.3109/03602532.2010.484462. [Article]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Inducer
General Function
Oxygen binding
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP3A5
Uniprot ID
P20815
Uniprot Name
Cytochrome P450 3A5
Molecular Weight
57108.065 Da
References
  1. Dvorak Z, Pavek P: Regulation of drug-metabolizing cytochrome P450 enzymes by glucocorticoids. Drug Metab Rev. 2010 Nov;42(4):621-35. doi: 10.3109/03602532.2010.484462. [Article]

Drug created on September 01, 2018 21:25 / Updated on May 15, 2021 22:43